Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Human vaccines & immunotherapeutics
- Publicado em
- 30 mai 2023
- Citações
- 10
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
Li-Wei Shi, Juan Li, Bang-Wei Yu, Li-Rong Huang, Ke Li, Min Ji, Ling-Yun Zhou, Lin Yuan, Shu-Yuan Yang, Jing-Jing Chen et al.
Descritores MeSH
- Papillomavirus Infections
- Papillomavirus Vaccines
- Adolescent
- Adult
- Antibodies, Viral
- Child
- Double-Blind Method
- Female
- Humans
- Middle Aged
Veja também
Estudos relacionados
- Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial
- Immunogenicity and safety of co-administered Escherichia coli-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine
- Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial
- Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls